Doha, Qatar –A signing ceremony was held at Abela Qatar International Headquarters, on 17 August, 2025, bringing together Rwanda Medical Supply (RMS), Labophar Ltd, and Philex Pharmaceuticals to formalize two strategic agreements. 

The first agreement established a Local Technical Representative (LTR) partnership between RMS and Philex Pharmaceuticals. Signed by Ms. Diana Mutoni, Deputy CEO of RMS, and Mr. Wassem Hamad, CEO & Partner at Philex Pharmaceuticals, this partnership positions RMS as Philex’s official representative in Rwanda. Through the agreement, RMS will ensure full regulatory compliance and facilitate the import and nationwide distribution of essential medical commodities, including oncology and cardiology medicines, as well as other specialized supplies, across all 30 districts of Rwanda.

In parallel, a joint venture and technology transfer agreement was signed between Labophar Ltd and Philex Pharmaceuticals to localize the production of Philex’s solid dosage forms in Rwanda. This milestone agreement was signed by Mr. Pascal Gatete, CEO of Labophar, and Mr. Waseem Hamad, CEO & Partner at Philex, marking an important step toward enhancing Rwanda’s pharmaceutical manufacturing capacity and reducing reliance on imports.

Both agreements were signed in the presence of the Ambassador of Rwanda to the State of Qatar, Mr. Igor Marara, alongside other distinguished guests and stakeholders.

Speaking at the ceremony, Ms. Diana Mutoni, Deputy CEO of RMS, emphasized: “The partnership with Philex will not only expand our portfolio of medicines but also ensure that our citizens have reliable access to the quality and affordable medicines they need.”

Together, these agreements reinforce Rwanda’s commitment to advancing healthcare delivery through both stronger supply chain systems and local production of essential medicines. They also highlight the growing partnership between Rwanda and Qatar, underscoring both countries’ shared vision of fostering innovation, resilience, and well-being for their people.